CN1160399A - 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途 - Google Patents

苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途 Download PDF

Info

Publication number
CN1160399A
CN1160399A CN95195608A CN95195608A CN1160399A CN 1160399 A CN1160399 A CN 1160399A CN 95195608 A CN95195608 A CN 95195608A CN 95195608 A CN95195608 A CN 95195608A CN 1160399 A CN1160399 A CN 1160399A
Authority
CN
China
Prior art keywords
alkyl
phenyl
compound
perfluoroalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN95195608A
Other languages
English (en)
Chinese (zh)
Inventor
马克·A·多姆布罗斯基
凯文·科克
安东尼·D·皮斯科皮奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1160399A publication Critical patent/CN1160399A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN95195608A 1994-10-13 1995-05-26 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途 Pending CN1160399A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32287694A 1994-10-13 1994-10-13
US08/322,876 1994-10-13

Publications (1)

Publication Number Publication Date
CN1160399A true CN1160399A (zh) 1997-09-24

Family

ID=23256829

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95195608A Pending CN1160399A (zh) 1994-10-13 1995-05-26 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途

Country Status (23)

Country Link
US (2) US6051601A (enExample)
EP (1) EP0785930A1 (enExample)
JP (1) JP2983295B2 (enExample)
KR (1) KR100232341B1 (enExample)
CN (1) CN1160399A (enExample)
AU (1) AU696890B2 (enExample)
BR (1) BR9504385A (enExample)
CA (1) CA2201742A1 (enExample)
CO (1) CO4480024A1 (enExample)
CZ (1) CZ111797A3 (enExample)
FI (1) FI971524A0 (enExample)
HU (1) HUT77515A (enExample)
IL (1) IL115529A0 (enExample)
MX (1) MX9702731A (enExample)
NO (1) NO971672L (enExample)
NZ (1) NZ285156A (enExample)
PE (1) PE10897A1 (enExample)
PL (1) PL319688A1 (enExample)
RU (1) RU2128655C1 (enExample)
TR (1) TR199501270A2 (enExample)
TW (1) TW304941B (enExample)
WO (1) WO1996011920A1 (enExample)
ZA (1) ZA958597B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102920692A (zh) * 2012-10-25 2013-02-13 中国人民解放军第二军医大学 (e)-2-(1-羟基-4-环己酮)乙基咖啡酸酯在制备防治类风湿关节炎的药物中的应用
CN119700747A (zh) * 2025-02-26 2025-03-28 云南农业大学 苦杏碱醇a在制备防治骨质疏松症产品中的应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2265043C (en) * 1996-09-16 2003-01-14 Pfizer Inc. Processes and intermediates for preparing substituted chromanol derivatives
WO1998025616A1 (en) * 1996-12-13 1998-06-18 Eli Lilly And Company Leukotriene antagonists for cerebral focal stroke
IL128731A0 (en) * 1998-03-12 2000-01-31 Pfizer Prod Inc Method of preventing allograft rejection
EP0963755A3 (en) * 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
BR0206771A (pt) * 2001-01-30 2004-02-25 Pfizer Prod Inc Processos para a preparação de cidos cromanilbenzóicos
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
MXPA04012711A (es) 2002-06-19 2005-03-23 Biovitrum Ab Nuevos compuestos, su uso y preparacion.
EP1773396A1 (en) * 2004-07-22 2007-04-18 Pharmacia Corporation Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
US7576094B2 (en) * 2004-12-13 2009-08-18 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
BRPI0520097A2 (pt) 2005-02-25 2009-08-25 Lilly Co Eli composto ou estereoisÈmeros únicos, misturas de estereoisÈmeros, ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
WO2007134149A2 (en) 2006-05-11 2007-11-22 Janssen Pharmaceutica N.V. 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
EP2034998A1 (en) 2006-05-11 2009-03-18 Janssen Pharmaceutica, N.V. 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
CA2864331C (en) 2012-02-14 2018-10-09 Children's Hospital Medical Center Use of small molecule inhibitors targeting the interaction between rac gtpase and p67(phox)
JP2018531213A (ja) 2015-03-13 2018-10-25 フォーマ セラピューティクス，インコーポレイテッド Ｈｄａｃ８阻害剤としてのアルファ−シンナミド化合物及び組成物
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
EP3383868B1 (en) 2015-11-30 2022-10-05 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
US10450309B2 (en) 2015-11-30 2019-10-22 Merch Sharp & Dohme Corp. Aryl sulfonamides as BLT1 antagonists
EP3383388B1 (en) 2015-11-30 2021-04-14 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
WO2017095723A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
US20190216790A1 (en) * 2016-10-13 2019-07-18 The Regents Of The University Of California Methods for Treating Pruritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU469247A3 (ru) * 1972-01-14 1975-04-30 Майлз Лабораториз Инк (Фирма) Способ получени производных хромона
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
CA1320490C (en) * 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
CA2019335C (en) * 1989-06-27 2000-08-01 Mitoshi Konno Phenylalkan (en)oic acids
US4996230A (en) * 1990-02-16 1991-02-26 Eli Lilly And Company Leukotriene antagonists
US5073562A (en) * 1990-05-10 1991-12-17 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
US5051438A (en) * 1990-05-16 1991-09-24 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
CA2117349C (en) * 1992-01-23 2000-02-29 Kevin Koch Benzopyrans and related ltb4 antagonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102920692A (zh) * 2012-10-25 2013-02-13 中国人民解放军第二军医大学 (e)-2-(1-羟基-4-环己酮)乙基咖啡酸酯在制备防治类风湿关节炎的药物中的应用
CN119700747A (zh) * 2025-02-26 2025-03-28 云南农业大学 苦杏碱醇a在制备防治骨质疏松症产品中的应用
CN119700747B (zh) * 2025-02-26 2025-05-06 云南农业大学 苦杏碱醇a在制备防治骨质疏松症产品中的应用

Also Published As

Publication number Publication date
JPH09512035A (ja) 1997-12-02
ZA958597B (en) 1997-04-14
WO1996011920A1 (en) 1996-04-25
FI971524A7 (fi) 1997-04-11
NO971672L (no) 1997-06-11
CO4480024A1 (es) 1997-07-09
TW304941B (enExample) 1997-05-11
EP0785930A1 (en) 1997-07-30
PL319688A1 (en) 1997-08-18
HUT77515A (hu) 1998-05-28
AU2416795A (en) 1996-05-06
TR199501270A2 (tr) 1996-06-21
AU696890B2 (en) 1998-09-24
KR970706270A (ko) 1997-11-03
US6051601A (en) 2000-04-18
RU2128655C1 (ru) 1999-04-10
NO971672D0 (no) 1997-04-11
BR9504385A (pt) 1997-05-27
JP2983295B2 (ja) 1999-11-29
PE10897A1 (es) 1997-04-21
US6133286A (en) 2000-10-17
CZ111797A3 (cs) 1998-07-15
IL115529A0 (en) 1996-01-19
CA2201742A1 (en) 1996-04-25
NZ285156A (en) 1999-01-28
MX9702731A (es) 1997-06-28
FI971524A0 (fi) 1997-04-11
KR100232341B1 (ko) 2000-07-01

Similar Documents

Publication Publication Date Title
CN1160399A (zh) 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
CN1166834A (zh) 苯并吡喃和苯并稠合化合物，其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
CN1037439C (zh) 制备具有神经保护作用的吲哚酮及有关衍生物的方法
CN1052723C (zh) 用作治疗剂的双环芳族化合物、其制法及含有该化合物的药物组合物
CN1340048A (zh) 异黄酮衍生物的制备
US5356905A (en) Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
CN1031230A (zh) 具有类视网膜活性的苯基和杂二环基取代的乙炔及其制备方法
CN87104970A (zh) 取代的氨基-5，6，7，8-四氢萘基氧代乙酸其制备方法及其作为药物的用途
CN86107627A (zh) 新颖的4-苄基-1-(2h)-酞嗪酮衍生物的制备方法
CN1553915A (zh) 制备六氢-呋喃并[2,3-b]呋喃-3-醇的方法
EP0623123B1 (en) Benzopyran and related LTB4-antagonists
CN1214048A (zh) 具有白细胞三烯拮抗作用的苯并吡喃衍生物
CN1071755C (zh) 杂环甲酰胺衍生物及其作为治疗剂的用途
CN1040440C (zh) 去氢环黄皮酰胺衍生物的制备方法
CN1118783A (zh) 新的吡啶并[3，2-b][1，5]苯并硫代吖庚因的制备方法
CN1024663C (zh) 治疗气喘用的取代的四氢化萘类化合物的制备方法
CN1123546A (zh) 4-芳基异吲哚止痛药
CN1535274A (zh) 抗抑郁的(SSSRI)7,8-二氢-3H-6,9-二氧杂-1,3-二氮杂环戊二烯并[a]萘的氮杂环基甲基衍生物
CN1043128A (zh) 取代的咪唑衍生物及其制备
CN1228082A (zh) 双吲哚基马来酰亚胺的合成
CN1117729A (zh) 吗啉衍生物
CN1102644A (zh) 缩合吡啶型甲羟戊酸内酯中间体及其制备方法
CN87102452A (zh) 1、4-二氢吡啶-3、5-二羧酸的不对称酯的衍生物
HK1000700A (en) Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists
CN1157822A (zh) 药物化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication